Hersh E M, Funk C Y, Petersen E A, Ryschon K L, Mosier D E
Section of Hematology, University of Arizona College of Medicine, Tucson 85724.
Int J Immunopharmacol. 1993 Feb;15(2):137-43. doi: 10.1016/0192-0561(93)90089-h.
Diethyldithiocarbamate (DTC) was used to treat the murine, retrovirus-induced, immunodeficiency disease (MAIDS). Once-weekly treatment was not effective and 800 mg/kg was toxic. When 200, 400 and 600 mg/kg were given i.p., 5 days per week, starting either on the day of virus inoculation or 14 days later, a dose-response and time-response relationship was noted. Higher doses and a 2-week delayed onset of treatment were generally more effective in reducing the development of lymphadenopathy, hypergammaglobulinemia and in prolonging survival than treatment started on the day of virus inoculation. When treatment was delayed until 10 weeks after virus inoculation existing lymphadenopathy was abrogated (treated node area 0 mm2 compared to control 175 mm2, P < 0.0001) and survival was improved (treated 100% compared to control 12.5%, P < 0.0001). However, when therapy was stopped animals died at the same rate as the untreated controls. These data indicate that DTC is active in MAIDS in a dose-responsive and time-dependent manner.
二乙基二硫代氨基甲酸盐（DTC）被用于治疗小鼠逆转录病毒诱导的免疫缺陷疾病（MAIDS）。每周一次的治疗无效，且800毫克/千克具有毒性。当分别以200、400和600毫克/千克的剂量腹腔注射给药，每周5天，在病毒接种当天或14天后开始给药时，观察到了剂量反应和时间反应关系。与在病毒接种当天开始治疗相比，更高的剂量和延迟2周开始治疗通常在减少淋巴结病、高丙种球蛋白血症的发展以及延长生存期方面更有效。当治疗延迟到病毒接种后10周时，现有的淋巴结病被消除（治疗组淋巴结面积为0平方毫米，而对照组为175平方毫米，P<0.0001），生存期得到改善（治疗组为100%，而对照组为12.5%，P<0.0001）。然而，当停止治疗时，动物的死亡速度与未治疗的对照组相同。这些数据表明，DTC在MAIDS中以剂量反应和时间依赖的方式发挥作用。
